Written by The Mycoplasma Testing Market is gaining momentum alongside the expansion of biologics, cell-based research, and advanced therapeutic manufacturing. Mycoplasma contamination can compromise cell cultures and biological production processes, making reliable testing an important part of laboratory quality control. Growing regulatory attention toward manufacturing quality is encouraging pharmaceutical and biotechnology organizations to adopt validated testing workflows.
Molecular testing technologies are playing an increasingly important role in market development. qPCR accounted for 59.10% of the market in 2025, benefiting from established validation procedures and regulatory acceptance. Digital PCR is projected to grow at a faster rate as laboratories seek improved sensitivity for low-copy contamination detection and more automated testing workflows.
By application, cell-line quality control represents a significant area of demand because testing is required during important cell-bank and manufacturing stages. Gene and cell therapy manufacturing is expected to show the highest growth as the number of advanced therapy programs increases. Biopharmaceutical and biotechnology companies remain major end users, while contract manufacturing organizations are expanding their testing capabilities to support outsourced production programs.
Regional development is also influencing the market outlook. North America accounted for approximately 43.10% of 2025 revenue, while Europe held around 27.80%. Asia-Pacific is projected to grow at a 16.50% CAGR through 2035, supported by expanding biomanufacturing infrastructure and laboratory investments. These developments are expected to encourage demand for rapid, automated, and scalable mycoplasma testing solutions.
Gain a competitive edge with insightful market reports:
Assistive Technology Market Size
Blood Gas And Electrolyte Analyzer Market Trends